CA-GLOBAL-CLEAN-ENERGY
3.1.2022 15:02:07 CET | Business Wire | Press release
Global Clean Energy Holdings, Inc., (OTCQX: GCEH), a vertically integrated renewable fuels company, today announced that it has acquired Camelina Company España S.L. (CCE), Europe’s largest camelina crop innovator and seed producer headquartered in Madrid, Spain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005073/en/
CCE has received international acclaim for more than 10 years by developing world class intellectual property (IP) in camelina to support a sustainable biofuels value chain. CCE’s IP includes superior genetics, breeding capabilities, high quality planting seed, advanced agronomic research, and knowledge to support the cultivation of camelina by contract farmers. CCE, together with Sustainable Oils, Inc. (SusOils), also a wholly owned subsidiary of GCE, will further enhance the company's portfolio of patented camelina genetics. CCE and SusOils have been collaborating for some time to expand and harmonize their collective research and development activities. The combined capabilities will accelerate the development of proprietary germplasm and varieties of camelina that will provide third-party contract camelina growers in North America, Western Europe and South America with additional revenue opportunities by sustainably increasing their fallow crop rotation options.
“The addition of CCE to our family of companies and its synergy with SusOils further advances our goal of increasing the commercial value of camelina through improved agronomics and plant genetics. Together, CCE and SusOils will build on our combined decades of camelina research and development activities that are focused on improving yield, reducing growing time, modifying plant oil chemistry to enhance biorefinery efficiency, and improving livestock feed qualities of camelina meal,” said Richard Palmer, GCE’s President & CEO “This acquisition demonstrates our ongoing commitment to investing both domestically and internationally in the science, infrastructure and farmer education necessary to deliver high-quality camelina feedstocks to satisfy the growing worldwide demand for renewable diesel and sustainable aviation fuels while not displacing food crops or impacting food security. This acquisition provides an established launching pad for our rapid expansion into Europe and South America.”
Established in 2010, CCE is Europe’s largest camelina crop innovator and seed producer. In 2013, it was the first global company to receive a sustainability certification from the Roundtable on Sustainable Biomaterials (RSB ), a global sustainability standard and certification system for biofuels and biomaterials production. The company has extensive expertise in camelina production along the complete value chain, having supplied sustainable and certified camelina oil for aviation biofuel production, as well as camelina meal, a high-quality plant based protein source for the livestock feed industry. The company maintains an ongoing plant breeding program with more than 600 camelina germplasm lines and owns nine proprietary camelina varieties, which enables the sustainable introduction of camelina in different crop rotations without displacing any primary crops.
“We are excited by the significant synergies that exist between CCE, GCE and SusOils,” said Yuri Herreras Yambanis, Director, CCE. “Combining the knowledge and expertise of our organizations provides us the opportunity to further advance camelina research and production in ways that deliver profitable and sustainable advantages for both regenerative agriculture and the renewable fuels industry.”
Camelina is an essential part of the feedstock plan for GCE’s integrated farm-to-fuels strategy. In early 2022, GCE will open a newly renovated renewable diesel biorefinery in Bakersfield, California, and supply ExxonMobil up to 220 million gallons annually of renewable diesel under a pair of long-term purchase agreements.
About Global Clean Energy Holdings, Inc.
Global Clean Energy Holdings, Inc. (“GCE” or “GCEH”) is a vertically integrated renewable fuels company specializing in nonfood-based feedstocks used for the production of advanced biofuels and biomaterials. With a footprint that stretches from the laboratory to the farm gate through to biorefinery production, GCE’s farm-to-fuels value chain integration provides unrivaled access to reliable, ultra-low carbon feedstocks. When online, the Bakersfield Biorefinery will be the only facility of its type, processing both traditional feedstocks as well as domestically produced camelina oil into sustainable, ultra-low carbon fuels in California. To learn more, visit gceholdings.com.
About Camelina Company España S.L.
Camelina Company España S.L. (CCE) has developed a sustainable camelina value chain: from breeding and planting seed production to agronomic expansion and camelina processing for advanced biofuel production. CCE introduces camelina into existing crop rotations without any food displacement - as a catch crop or replacement of traditional fallow periods - employing its proprietary camelina varieties and prediction models to optimize its elite varieties in different cropping systems, primarily in Europe and South America. CCE was established in 2010 and is headquartered in Madrid, Spain. To learn more, visit camelinacompany.es.
About Sustainable Oils, Inc.
Sustainable Oils, Inc. (SusOils), GCEH’s wholly owned plant science subsidiary, owns an industry-leading portfolio of intellectual property, including patents and production know-how, to produce its proprietary varieties of camelina, a nonfood based ultra-low carbon biofuels feedstock. SusOils’ corporate headquarters are located in Great Falls, Montana. To learn more, visit susoils.com.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Global Clean Energy Holdings, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements are forward-looking statements and are subject to a number of risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
